Regional differences in presentation of AIDS in Europe

Data were collected on 6578 patients diagnosed with AIDS at 52 clinical centres in 17 European countries during an 11-year period from 1979 to 1989. The centres were divided into four regions, North, Central, Southeast, and Southwest. Differences in the incidence of most AIDS-defining opportunistic infections and malignancies were found. After adjusting for known possible confounders, statistically significant differences between regions remained. Pneumocystis carinii pneumonia (PCP) was more common in Northern Europe, Kaposi's sarcoma and toxoplasmosis in Central Europe, cytomegalovirus retinitis in South-eastern Europe, and extrapulmonary tuberculosis in South-western Europe. These differences we attribute primarily to different degrees of exposure to the respective underlying pathogens. The prevalence of these and other micro-organisms will determine the clinical course of HIV infections in parts of Eastern Europe and elsewhere where the virus now is spreading.

[1]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[2]  H. Brodt,et al.  Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival , 1998, AIDS.

[3]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[4]  D. Burke,et al.  Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[5]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[6]  S. Ebrahim,et al.  Geography of AIDS‐associated Kaposi's sarcoma in Europe , 1997, AIDS.

[7]  A. Mocroft,et al.  Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. , 1997, International journal of epidemiology.

[8]  S. Krown.  Acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Biology and management. , 1997, The Medical clinics of North America.

[9]  J. Margolick,et al.  Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[10]  S. Mallal,et al.  Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort , 1996, AIDS.

[11]  A. d’Arminio Monforte,et al.  Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study Group. , 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  A. Tosteson,et al.  The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS , 1996, AIDS.

[13]  C. Katlama,et al.  Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group. , 1996, AIDS.

[14]  R. Chaisson,et al.  Duration of the survival benefit of zidovudine therapy in HIV infection. , 1996, Archives of internal medicine.

[15]  J. Phair,et al.  Projecting disease when death is likely. , 1996, American journal of epidemiology.

[16]  J. Goedert,et al.  Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infection , 1996, Nature Medicine.

[17]  P. Hartigan,et al.  Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: Report of a Veterans Affairs Cooperative Study , 1996 .

[18]  C. Katlama,et al.  HIV‐related non‐Hodgkin's lymphoma among European AIDS patients , 1995, European journal of haematology.

[19]  A. Phillips,et al.  Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Z. Bentwich,et al.  Immune activation is a dominant factor in the pathogenesis of African AIDS. , 1995, Immunology today.

[21]  R. Sherer.  A Sex Comparison of Rates of New AIDS-Defining Disease and Death in 2554 AIDS Cases , 1994 .

[22]  J. Phair,et al.  The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. , 1994, JAMA.

[23]  A. Phillips,et al.  A sex comparison of rates of new AIDS‐defining disease and death in 2554 AIDS cases , 1994, AIDS.

[24]  J. Nielsen,et al.  Survival differences in European patients with AIDS, 1979–89 , 1994, BMJ.

[25]  Anne M Johnson,et al.  Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine , 1994 .

[26]  J. Nielsen,et al.  Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. , 1994, JAMA.

[27]  J. Phair,et al.  Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. , 1993, American journal of epidemiology.

[28]  J. Kaldor,et al.  Long-term symptomless HIV-1 infection in recipients of blood products from a single donor , 1992, The Lancet.

[29]  K. Ma,et al.  Penicillium marneffei: indicator disease for AIDS in South East Asia. , 1992, AIDS.

[30]  M. Zeckel,et al.  Disseminated Histoplasmosis in the Acquired Immune Deficiency Syndrome: Clinical Findings, Diagnosis and Treatment, and Review of the Literature , 1990, Medicine.

[31]  J. Phair,et al.  Serologic responses to Pneumocystis carinii antigens in health and disease. , 1990, The Journal of infectious diseases.

[32]  J. Murray,et al.  The white plague: down and out, or up and coming? J. Burns Amberson lecture. , 1989, The American review of respiratory disease.

[33]  E. van Marck,et al.  Persistent diarrhoea in Zairian AIDS patients: an endoscopic and histological study. , 1988, Gut.

[34]  A. Infuso,et al.  Diversity of the HIV/AIDS epidemic in Europe. , 1998, AIDS.

[35]  I. Bain.  South-East Asia. , 1998, International migration.

[36]  P. Zuber,et al.  Epidémiologie de la toxoplasmose: situation au niveau mondial. , 1995 .

[37]  James Chang.  Opportunistic Infections in Patients with the Acquired Immunodeficiency Syndrome , 1990, The Yale Journal of Biology and Medicine.